This week covers Japanese reimbursement proposals and endoscopy business results alongside US regulatory review, a product launch, financing and an acquisition agreement. Announcement dates are distinguished from clearance, reimbursement and transaction completion.
1. Japan presents three devices for planned December reimbursement
Material date: 2026-11-11
Japan’s MHLW presented proposed reimbursement classifications and prices for Menicon’s Varte, Edwards’ SAPIEN 3 Ultra RESILIA system and Nissin’s Bellezza Titanium, with listing planned for December 1. The material describes proposals, not reimbursement already in effect.
2. Novocure reports a Not Approvable Letter for Optune Mya
Publication date: 2026-11-09
Novocure reported an FDA Not Approvable Letter for Optune Mya’s PMA in NSCLC brain metastases following stereotactic radiation. According to the company, uncertainty concerned the magnitude of clinical benefit, with no safety-profile concerns raised. Approval has not been obtained.
3. Medtronic announces US rollout of Aristotle Mini
Publication date: 2026-11-09
Medtronic announced a phased US introduction of the Aristotle Mini guidewire following August 510(k) clearance. It targets small distal neurovascular access and compatibility with microcatheters having a 0.013-inch inner diameter. That measurement is not the guidewire’s outer diameter.
4. Olympus reports growth in gastrointestinal endoscopy
Publication date: 2026-11-10
Olympus reported fiscal-year-ending-March-2027 second-quarter gastrointestinal endoscopy sales of ¥184.5 billion, up 10% as reported and 2% currency-neutral. Quality-system remediation and dialogue with the FDA continue; this announcement does not establish that import restrictions have been lifted.
5. Francis Medical announces JJDC-led financing agreement
Publication date: 2026-11-10
Francis Medical announced an undisclosed JJDC-led financing agreement supporting Vanquish’s US expansion and prostate-cancer-management PMA development. Its existing 510(k) clearance covers thermal ablation of prostate tissue, not FDA approval for treating prostate cancer.
6. Oura agrees to acquire Counsel Health for $625 million
Publication date: 2026-11-10
Oura signed a definitive agreement to acquire Counsel Health for $625 million in cash, subject to adjustments and closing conditions. Completion is expected before year-end, not already achieved. The strategy connects biometrics with AI-supported physician care; Oura Ring is not a medical device.
Summary
Reimbursement proposals, FDA decisions, commercial introductions and corporate transactions represent different stages of progress. Announcements alone should not be read as proof of a new treatment indication, completed deal or established business outcome.